PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
|
|
- Randall Jones
- 5 years ago
- Views:
Transcription
1 bs_bs_banner International Journal of Urology (214) 21, doi: /iju Original Article: Clinical Investigation PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer Prabhakar Mithal, 1,4 Emma Allott, 2,4 Leah Gerber, 2 Julia Reid, 3 William Welbourn, 3 Eliso Tikishvili, 3 Jimmy Park, 3 Adib Younus, 3 Zaina Sangale, 3 Jerry S Lanchbury, 3 Steven Stone 3 and Stephen J Freedland 2,4 1 University of Massachusetts Medical School, Worcester, Massachusetts, 2 Duke University, Durham, North Carolina, 3 Myriad Genetics, Salt Lake City, Utah, and 4 Surgery Department, Durham VA Medical Center, Durham, North Carolina, USA Abbreviations & Acronyms ADT = androgen deprivation therapy BCR = biochemical recurrence CRPC = castration-resistant prostate cancer PC = prostate cancer PCSM = prostate cancer specific mortality PSA = prostate-specific antigen RP = radical prostatectomy TURP = transurethral resection of the prostate Correspondence: Stephen J Freedland M.D., Departments of Surgery and Pathology, Duke University Medical Center, DUMC Box 2626, Suite 457, MSRB-I, 571 Research Drive, Durham, NC 2771, USA. steve.freedland@duke.edu Received 17 December 213; accepted 17 June 214. Online publication 5 August 214 Objectives: To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long-term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. Methods: In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between , biopsy samples were stained for PTEN expression by the PREZEON assay with >1% staining reported as positive. Cox proportional hazards and log rank models were used to assess the correlation between PTEN loss and clinical outcomes. Results: During a median follow-up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration-resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval.9 5.1, P =.1), but significantly predicted increased risk of castration-resistant prostate cancer, metastasis and prostate cancer-specific mortality (all log rank, P <.1), and time from androgen deprivation therapy to castration-resistant prostate cancer (log rank, P =.3). No patient without PTEN loss developed metastases or died from prostate cancer. Conclusions: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer. Key words: biochemical recurrence, castration-resistant prostate cancer, prostate cancer, PTEN, prostate cancer-specific mortality. Introduction The need for better risk stratification in PC is well established. Despite the use of PSA, Gleason score and clinical staging, a substantial number of men with PC continue to be both under-and overtreated. 1 Thus, in order to better differentiate aggressive from indolent PC, clinicians are in need of more reliable molecular markers. A growing body of evidence suggests that the PTEN gene, a tumor suppressor that regulates the PI3K/p-AKT pathway, is one of the most commonly deleted genes in PC In animal models, complete PTEN loss recapitulates the major hallmarks of aggressive human PC local tumor invasion, metastases and castration resistance. 13 The role of PTEN in human PC progression is supported by multiple studies showing PTEN loss is more frequent in metastatic CRPC compared with localized PC. 6,11,12,14,15 However, it is unknown whether PTEN loss in localized tumor can help identify which men are at increased risk of future CRPC development. To understand the prognostic significance of PTEN, multiple studies have examined RP tissue and have shown that PTEN loss in the RP specimen is prognostic for BCR, an intermediate end-point. 3,5,1,11,16,17 However, given the marked tumor heterogeneity in PC, it is unclear whether using the more limited amount of tissue available in biopsy samples can yield similar prognostic information. The one study to date that examined this found no significant association between PTEN loss and BCR The Japanese Urological Association 129
2 P MITHAL ET AL. (a) (b) Fig. 1 Images taken at 2 magnification of biopsy samples stained by the PREZEON assay (Myriad Genetics). (a) PTEN-negative prostate biopsy tissue. (b) PTEN-positive prostate biopsy tissue. Furthermore, although BCR is an end-point linked with later outcomes, 19 not all men with BCR progress. As such, it is noteworthy that the two prior studies that examined the association of PTEN loss with clinical outcomes beyond BCR found that PTEN loss in the primary resected tumor predicted the development of metastatic disease among high-risk, but not PCSM in lower-risk men. 8,9 However, this has never been tested using biopsy tissue. Collectively, the prior studies leave open two key unanswered questions: (i) Can PTEN loss in the biopsy tissue predict clinical outcomes? and (ii) Can PTEN loss predict outcomes beyond BCR? To address these questions, we carried out a pilot study using an immunohistochemistry technique previously shown to be reliable, sensitive and specific for PTEN loss to assess whether PTEN status in diagnostic prostate biopsy tissue samples is associated with clinical outcomes in PC. 2 Furthermore, given that a recent study in mice with early-stage disease and PTEN loss suggested that ADT might actually accelerate disease progression, 21 we tested whether PTEN status predicted responses to ADT. Methods Study population and tissue samples A retrospective analysis was carried out in 77 men who underwent a diagnostic biopsy between 1992 and 26 and were subsequently treated by RP at the Veterans Affairs Medical Center in Durham, North Carolina, USA. The entry criteria for the present study included treatment between 1992 and 26, treatment <2 years after biopsy, no adjuvant radiation or hormonal therapy and 3 years of follow up or BCR within that time. Clinical and pathological variables PTEN protein expression levels were assessed in formalin-fixed paraffin embedded biopsy samples by immunohistochemistry assay, PREZEON (Myriad Genetics, Salt Lake City, UT, USA). This assay uses a rabbit monoclonal antibody, which detects endogenous levels of total PTEN protein. 2 PSA (ng/ml) values were obtained from the measurement closest to the date of, but preceding RP. BCR was defined as a single PSA value >.2 ng/ ml, two values of.2 ng/ml or secondary treatment for an elevated postoperative PSA. Distant metastases, defined as bone or visceral or distant (non-pelvic) adenopathy, were determined by review of radionuclide bone scans, magnetic resonance imaging scans, computed tomography scans, plain radiograph reports and clinical progress notes. The decision to carry out radiographic imaging was at the attending physician s discretion. CRPC was defined using the Prostate Cancer Working Group 2 criteria: a 25% PSA increase from the nadir and an increase of 2 ng/ml. PCSM was defined as death in any patient with metastasis showing progression after ADT. All information relevant to study variables was ascertained from medical records. Statistical analysis The tumor was considered PTEN negative ( ) if <1% of the tumor cells stained for PTEN expression and PTEN positive ( 1 ) otherwise (Fig. 1). This method was used because it reflected the distinctly bimodal staining pattern seen. Group characteristics were compared using the two-sample t-test for normally distributed continuous variables, Wilcoxon rank-sum test for non-normally distributed continuous variables and Fisher s exact test for categorical variables. Kaplan Meier plots and the log rank test were used to assess the correlation between PTEN loss and BCR (our primary outcome). Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals of PTEN loss in predicting BCR. As our goal was to assess whether PTEN status in the biopsy could predict outcomes, we did not adjust for pathological characteristics in the RP specimen. In secondary analysis, we evaluated the association between PTEN loss and the development of CRPC, metastasis, PCSM, receipt of ADT after RP or response to ADT. To determine how well PTEN loss could predict future receipt of ADT receipt or response to ADT, we calculated the c-index. Because of the limited number of events for the studied outcomes, only univariable analyses were carried out. Two-sided P-values <.5 were considered statistically significant. Results Clinical characteristics of patient cohort The clinical characteristics of the study population are summarized in Table 1. Of the 77 men, nine (12%) had PTEN loss. PTEN status and clinical outcomes During a median follow-up period of 8.8 years, 39 men (51%) developed BCR, 2 men (26%) went on to receive ADT, four (5%) had CRPC, and two (3%) had progressed to metastatic disease and eventually died from PC. In our primary analysis, PTEN loss was suggestively, but not significantly, associated with higher risk of BCR (HR 2.1, 95% CI.9 5.1, P =.96; Fig. 2a). After adjusting for biopsy Gleason score, the associa The Japanese Urological Association
3 PTEN loss at biopsy predicts PC outcomes Table 1 Clinical and pathological characteristics of patients in radical prostatectomy cohort Characteristic PTEN-positive PTEN-negative P-value Total n 68 9 Mean age at surgery, years (SD) 62. (±5.5) 6.6 (±6.9).39 Race, n (%).44 Non-black 32 (47%) 3 (33%) Black 36 (53%) 6 (67%) Median PSA, ng/ml (IQR) 6.8 ( ) 7.1 (2.9 1.).4 Biopsy Gleason score, n (%) (54%) 2 (22%) 7 28 (41%) 4 (44%) (4%) 3 (33%) Median percent positive biopsy tissue (IQR) (n = 48) 1 (5 2) 3 (13 58).8 Median percent positive biopsy cores (IQR) (n = 64) 45 (29 5) 5 (29 57).6 Clinical stage (n = 66).82 T1 33 (55%) 3 (5%) T2/T3 27 (45%) 3 (5%) Median surgery year (IQR) 22 ( ) 1998 ( ).4 Pathological Gleason score (19%) 1 (11%) 7 44 (65%) 8 (89%) (16%) Extracapsular extension 2 (3%) 6 (67%).3 Positive margins 45 (66%) 7 (77%).49 Seminal vesicle invasion 1 (15%) 3 (38%).12 Median follow-up years (IQR) 8.7 ( ) 9.4 ( ).55 Unpaired t-test; χ 2 -test; rank-sum. (a) Proportion without BCR Log-rank P= PTEN positive PTEN loss (c) Proportion without metastasis Log-rank P< PTEN positive PTEN loss (b) Proportion without CRPC Log-rank P< PTEN positive PTEN loss (d) Proportion surviving Log-rank P< PTEN positive PTEN loss Fig. 2 (a) BCR-free survival in RP patients grouped by PTEN status at the time biopsy. (b) CRPC-free survival in RP patients grouped by PTEN status at biopsy. (c) Metastasis-free survival in RP patients grouped by PTEN status at biopsy. (d) Prostate cancer-specific survival in RP patients grouped by PTEN status at biopsy., PTEN-positive;, PTEN loss. tion with PTEN loss remained insignificant, and the hazard ratio was decreased only slightly (HR 1.87, 95% CI , P =.196). The slight attenuation in the hazard ratio was expected given PTEN correlated with biopsy Gleason scores (P =.2) and biopsy Gleason score correlated with BCR risk (HR 1.7, 95% CI , P =.12). In secondary analysis, PTEN loss was significantly associated with increased risk of several hard clinical end-points including the development of 214 The Japanese Urological Association 1211
4 P MITHAL ET AL. (a) Proportion without ADT Log-rank P=.4 (b) Proportion without CRPC Log-rank P= PTEN positive PTEN loss PTEN positive PTEN loss Fig. 3 (a) ADT-free survival in RP patients grouped by PTEN status at biopsy. (b) CRPC-free survival in RP patients receiving ADT grouped by PTEN status at biopsy., PTEN-positive;, PTEN loss. CRPC, development of metastasis and increased risk of death from PC (all log rank, P <.1; Fig. 2b d). No patient without PTEN loss developed metastatic disease or died from PC (Fig. 2b,c). Among six men with biopsy Gleason 8 disease, the three with PTEN loss all developed CRPC, whereas all three with intact PTEN did not (log rank, P =.6). PTEN status and response to hormonal therapy A recent study suggested that in mice with PTEN loss, ADT could actually accelerate disease progression. 22 Given that PTEN appeared to be more strongly correlated with post-adt end-points (i.e. CRPC, metastasis and PCSM) than pre-adt end-points (i.e. BCR), we evaluated this hypothesis. We found that while PTEN loss significantly predicted the receipt of ADT (log rank, P =.4; Fig. 3a), it was much more strongly linked with the time from ADT to development of CRPC (log rank, P =.3; Fig. 3b). The c-index for PTEN loss to predict time from surgery to receipt of ADT was.57 versus.76 for predicting time to CRPC from ADT initiation. Discussion Although PTEN loss in RP tissue has been consistently correlated with BCR, this has not been well tested in biopsy tissue. The sole study evaluating biopsy tissue and outcomes found that PTEN loss was not significantly prognostic for BCR. 18 Therefore, we examined biopsy tissue from men undergoing RP and found that PTEN loss occurred not infrequently (12%), only suggestively predicted BCR, but strongly predicted later outcomes including CRPC, metastases and PCSM after RP. As such, this is the first study to show that PTEN loss in the biopsy tissue is a significant prognostic variable in PC. Given the small sample size, these findings require validation. However, if confirmed by larger studies, these results suggest that assessing PTEN status by immunohistochemistry could greatly improve assessment of patient prognosis at the time of biopsy, while also offering guidance regarding initial treatment selection. PTEN is one of the most potent tumor suppressors known in human cancer. 22 First identified in human cancers as a frequent deletion on chromosome 1, preclinical studies have shown PTEN to be a negative regulator of the PI3K/AKT/mTOR pathway, the activation of which is implicated in 3 5% of human PC. PTEN deletions in rodents lead directly to the development of an aggressive PC with metastases and the development of castrate resistance after ADT. 13 As a result, PTEN has been investigated increasingly in human PC tissue with studies having repeatedly shown that PTEN loss in the RP occurs at rates of 16 44% in clinically localized PC, and is associated with markers of aggressive PC including higher Gleason score, higher clinical stage, larger tumor size, extracapsular extension and seminal vesicle invasion Rates of PTEN loss are much higher in CRPC and metastases at 5 86%, and several smaller studies have even shown significantly increased loss in CRPC and metastases relative to primary tumors within a given patient. 3,5,6,1,11,16,17 These findings have bolstered interest in PTEN as an early marker of aggressive PC. Of note, in the present study the rate of PTEN loss in biopsy samples was 12%, a rate lower than in prior studies. This could simply reflect sampling error. However, given that the risk of PCSM after RP is 15% at 15 years, any marker that is altered in greater or lower than 15% of men risks over- or underestimating the true prevalence of aggressive disease, respectively. 23 As such, a 12% rate of PTEN loss approximates the prevalence necessary for a clinically useful prognostic biomarker in early stage PC. While linking PTEN loss to pathological measures of aggressiveness in localized PC or showing that PTEN loss is increased in CRPC or metastases can provide insight into PC biology, few conclusions can be drawn for the purposes of risk assessment, for several reasons. First, this information is restricted to the select group of men who choose RP. Second, linking PTEN loss with pathological features is less than ideal given that pathological features themselves are not perfect predictors of clinical outcome. 1 Third, the increased rates of PTEN loss in CRPC and metastases hint at an association with PC progression, but cannot help us understand the prognostic value of PTEN loss. Fourth, showing that PTEN loss correlates with other features of aggressive disease within the RP specimen (i.e. stage and grade) does not mean that PTEN enhances these features in terms of predicting future events (i.e. PC progression). Therefore, PTEN status must be evaluated independently of grade and stage, at earlier time-points The Japanese Urological Association
5 PTEN loss at biopsy predicts PC outcomes and in relation to future clinical outcomes. In line with this, studies examining RP tissue have consistently shown that PTEN loss independently predicts increased future risk of BCR, and that the prognostic information is improved when combined with other biomarkers, such as AKT and ERG. 3,5,1,11,16,17,24 However, just two prior studies using BCR as the primary end-point examined PTEN status in non-rp tissue. Zafarana et al. studied 126 intermediate-risk PC patients undergoing radiotherapy to assess whether PTEN loss and/or c-myc gain were predictive of BCR risk using prostate biopsy tissue. 18 They found that having either a PTEN loss or c-myc gain resulted in significantly increased BCR risk, but importantly that PTEN loss alone did not predict BCR. Reid et al. showed that in TURP specimens from 38 patients receiving no initial treatment and treated conservatively for PC, PTEN loss alone did not predict significantly increased risk of 11-year PCSM. 8 Interestingly, and analogous to the only other study to use pretreatment tissue, Reid et al. noted that PTEN became prognostic only when it was combined with a lack of ERG/ETV1 rearrangement to identify a high-risk cohort. Thus, the prior studies using biopsy or TURP tissue suggest that evaluating PTEN loss might have value. Consistent with both of these studies, we did not find PTEN loss alone to significantly predict BCR risk. Although BCR is a key determinant of PC management, and precedes CRPC, metastasis and PCSM, a significant number of patients who recur do not progress. 19 Thus, directly identifying patients most likely to progress to CRPC, metastasis and PCSM, rather than relying on BCR, should provide more accurate risk stratification. Of the four prior studies investigating PTEN in localized tumor predicting these later clinical endpoints, three have done so in high-risk cohorts. Lotan et al. showed that in a cohort with known BCR, PTEN loss in RP tissue was associated with decreased time to metastasis. 9 In that cohort, 27% of patients had Gleason scores of 8 or higher, whereas 86% had extracapsular extension. Similarly, two studies reporting PTEN as an independent predictor of PCSM did so in cohorts of CRPC patients. 11,15 That PTEN was able to predict earlier metastasis and PCSM even in high-risk cohorts suggests that it could help identify patients with particularly poor outcomes. By contrast, the one prior study of later clinical outcomes in a relatively low-risk group showed that in TURP specimens from patients receiving no initial treatment and treated conservatively for PC, PTEN loss alone did not predict increased risk of 11-year PCSM. 8 The present study is the first to show that even within the limitations of biopsy tissue, PTEN loss can predict future development of CRPC, metastasis and PCSM. The identification of PTEN loss as a predictor of CRPC is of particular importance given the poor prognosis of CRPC patients. PTEN is believed to be the most frequently deleted gene in CRPC, with rates of PTEN loss between 52 86%. 11,12,14,15 Furthermore, multiple studies have implicated PTEN loss in molecular pathways leading to CRPC, such as decreased androgen receptor expression, as well as androgen-independent cell survival. 13,25,26 PTEN loss might promote the clonal proliferation of castration-resistant tumor foci while hindering responses to ADT. Remarkably, a recent preclinical study showed that in PTEN-null mice, high-grade prostatic intraepithelial neoplasia rapidly progressed to aggressive CRPC in response to castration, whereas no such transformation occurred in castration-naive animals. 21 The implication of castration and PTEN loss together in the development of CRPC led us to hypothesize that PTEN loss could both contribute to the development of CRPC and predict which patients among those receiving ADT developed CRPC. Indeed, PTEN loss at biopsy strongly predicted reduced time to CRPC development after receipt of ADT (c-index.76). Though the interaction between PTEN loss and ADT in the development of CRPC requires further investigation and confirmation in larger studies, if the strong prognostic value of PTEN loss for predicting the development of CRPC were confirmed, it would provide a compelling argument for PTEN testing when considering the initiation of ADT. The present study had several limitations. Given that PC is a genetically heterogeneous, multifocal disease any biopsy study of PC is limited by sampling errors. Also, the number of men included in the current pilot study was modest, resulting in limited statistical power and precluding multivariable analysis. Larger studies are required to validate these findings and to test whether the prognostic information provided by PTEN is independent of other clinical characteristics something we could not test because of the small sample size. Despite this, we still were able to detect differences in PC outcomes, which are consistent with prior studies. Of note, for BCR, which had the most events, adjusting for Gleason only slightly affected the hazard ratio, suggesting it is not a major confounder of PTEN loss for BCR risk. Though PTEN loss correlated with biopsy Gleason, it did not with pathological Gleason, which could reflect either small sample size or the well-known disparity between biopsy and pathological Gleason scores. Whether similar results would be seen for the later outcomes is unknown. Finally, our cohort included only men undergoing RP, and additional studies will be required to validate these findings in other patient populations including men treated with external beam radiation or brachytherapy, or those enrolled in active surveillance. In conclusion, we show that although PTEN loss is an uncommon event in early stage PC, it was not rare (12%). For the first time, we show that PTEN loss can predict CRPC and response to ADT after RP. Furthermore, PTEN loss in the biopsy predicted time to development of metastasis and PCSM, findings consistent with prior studies. If confirmed in larger studies, these findings would support the use of PTEN loss as an early marker of aggressive PC. Conflict of interest None declared. References 1 Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur. Urol. 212; 61: McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999; 59: The Japanese Urological Association 1213
6 P MITHAL ET AL. 3 Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res. 23; 9: Dreher T, Zentgraf H, Abel U et al. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch. 24; 444: Yoshimoto M, Cunha IW, Coudry RA et al. FISH analysis of 17 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 27; 97: Schmitz M, Grignard G, Margue C et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 27; 12: Bismar TA, Yoshimoto M, Vollmer RT et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 211; 17: Reid AH, Attard G, Ambroisine L et al.; Transatlantic Prostate Group. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 21; 12: Lotan TL, Gurel B, Sutcliffe S et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin. Cancer Res. 211; 17: Chaux A, Peskoe SB, Gonzalez-Roibon N et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod. Pathol. 212; 25: McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer 28; 99: Han B, Mehra R, Lonigro RJ et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 29; 22: De Velasco MA, Uemura H. Preclinical remodeling of human prostate cancer through the PTEN/AKT pathway. Adv. Urol. 212; 212: Article ID pages. 14 Holcomb IN, Young JM, Coleman IM et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 29; 69: Sircar K, Yoshimoto M, Monzon FA et al. PTEN genomic deletion is associated with p-akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 29; 218: Yoshimoto M, Joshua AM, Cunha IW et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 28; 21: Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 212; 12: Zafarana G, Ishkanian AS, Malloff CA et al. Copy number alterations of c-myc and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 212; 118: Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 25; 294: Sangale Z, Prass C, Carlson A et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl. Immunohistochem. Mol. Morphol. 211; 19: Jia S, Gao X, Lee SH et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 213; 3: Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 212; 13: Wilt TJ, Brawer MK, Jones KM et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 212; 367: Bedolla R, Prihoda TJ, Kreisberg JI et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin. Cancer Res. 27; 13: Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA. PTEN-mediated pathways and their association with treatment-resistant prostate cancer (Review). BJU Int. 29; 14: Dong JT, Li CL, Sipe TW, Frierson HF Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res. 21; 7: The Japanese Urological Association
Introduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationValidation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationPCa Commentary. Volume 83 September October 2013
1221 Madison Street, First Floor Seattle, WA 98104 P 206-215-2480 ww.seattleprostate.com PCa Commentary Volume 83 September October 2013 Table of Contents Alpharadin, Xofigo Page 1 PTEN gene Page 3 ALPHARADIN
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationExpanded criteria for active surveillance in prostate cancer: a review of the current data
Review Article Expanded criteria for active surveillance in prostate cancer: a review of the current data Cameron Jones 1, Mina M. Fam 2, Benjamin J. Davies 2 1 University of Pittsburgh School of Medicine,
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationMultigene Testing in Prostate Cancer Risk Stratification
Multigene Testing in Prostate Cancer Risk Stratification Ashley Ross, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Objectives Briefly review relevant molecular biology of localized
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationPTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features
Picanço-Albuquerque et al. Applied Cancer Research (2019) 39:1 https://doi.org/10.1186/s41241-018-0071-y Applied Cancer Research RESEARCH ARTICLE PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Prognostic value of HER2/neu expression in patients with prostate cancer:
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-16-1-0737 TITLE: Developing a PTEN-ERG Signature to Improve Molecular Risk Stratification in Prostate Cancer PRINCIPAL INVESTIGATOR: Tamara Lotan CONTRACTING ORGANIZATION: Johns Hopkins
More informationDEGREE (if applicable) BS MD
NAME: Stephen J. Freedland, MD OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors.
More informationResearch Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationResults From the SEARCH Database
Cigarette Smoking Is Associated With an Increased Risk of Biochemical Disease Recurrence, Metastasis, Castration- Resistant Prostate Cancer, and Mortality After Radical Prostatectomy Results From the SEARCH
More informationCAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy
Original research CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy Michel Zimmermann, MD; 1 Guila Delouya, MD, MSc; 1,2 Abdullah M. Alenizi, MD;
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationBJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis
BJUI BJU INTERNATIONAL Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson and
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationMolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
MolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer Noridian Healthcare Solutions, LLC Please Note: This is a Proposed LCD. Proposed LCDs are works in progress
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More information